Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $186M (up 39.6% year over year) with net income of −$41M.
Q3 2026 key financials · XBRL
- Revenue
- $186M
- +39.6% YoY · +5.4% QoQ
- Net income
- −$41M
- −1503.3% YoY · +39.4% QoQ
- Operating margin
- -32.2%
- EPS (diluted)
- −$0.32
- −557.1% YoY · +46.7% QoQ
Source: XBRL data from the Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 10-Q on SEC EDGAR. USD.
Mirum Pharmaceuticals, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $185.7M, up $52.7M YoY from $133.0M
- Net loss $40.8M vs $2.9M net income; operating margin -32.2% vs 2.0%
- Best performer Livmarli: $133.4M, up $41.2M; Bile Acid Medicines $52.3M, up $11.5M
- Cash, equivalents and investments $500.5M vs $391.4M at December 31, 2025; nine-month operating cash flow -$277.3M
- Outlook: cash sufficient through at least next 12 months; continued net losses and higher brelovitug development spending expected
Risk Factors
- New regulatory risk: July 2026 FDA Form 483 cited untimely expedited adverse-event reports by Mirum and its pharmacovigilance vendor
- Most material update: FDA recommended a Phase 3 volixibat PSC study, delaying the planned NDA submission based on VISTAS data
- Market-access risk: Medicare negotiation, Most-Favored-Nation pricing proposals and German orphan-drug threshold reduction to €30 million
- Competitive risk: LIVMARLI generic ANDA filings triggered four 2025 patent complaints and a 2026 tablet litigation
- Financial risk: nine-month 2026 net loss $898.1 million, accumulated deficit $1.6 billion as continued losses are expected
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Mirum Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.